ANGO_OUT_1 [2025-04-02 11:32:28 -0400] 2410 Bytes | 651 tokens | Cum: 651 tkns (8.14% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 11:32:27 AM on Wed Apr 02, 2025 -0400, and I'm firing up the spotlight on AngioDynamics (ANGO), moving from 9.66 to 11.015. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: AngioDynamics (ANGO)
IPO: 2004-05-27 (20 Years Ago)
Market Cap: $437,373,616
Shares Outstanding: 40,630,000
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange: XNAS
Description: AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

Here's the first list of news for AngioDynamics:

C1 - Today 10:20AM - AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript
C2 - 07:40AM - AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates
C3 - 06:37AM - AngioDynamics: Fiscal Q3 Earnings Snapshot
C4 - 06:30AM - AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results
C5 - Mar-31-25 08:00AM - AngioDynamics to Host Virtual Cardiovascular Investor Event
C6 - Mar-26-25 09:40AM - Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?
C7 - Mar-19-25 08:00AM - AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event
C8 - Mar-10-25 04:30PM - AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on AngioDynamics (ANGO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ANGO_OUT_3 [2025-04-02 11:32:29 -0400] 410 Bytes | 138 tokens | Cum: 791 tkns (9.89% of 8k)
==========================================================================

Showing C2 (chunk 1 of 1): C2:
**AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates**
Date: 07:40AM
Source: (Zacks)
URL: /news/14795/angiodynamics-ango-tops-q3-earnings-and-revenue-estimates

**No additional content available.**

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ANGO_OUT_5 [2025-04-02 11:32:30 -0400] 998 Bytes | 290 tokens | Cum: 1110 tkns (13.88% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T14:48:21Z - Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Gu...
A2 - 2025-04-02T14:30:04Z - AngioDynamics Stock Rockets On Upbeat Q3, Improved Full-Year Guidance - But Retail Sentiment Plummet...
A3 - 2025-04-02T14:13:46Z - Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Mo...
A4 - 2025-04-02T13:50:23Z - AngioDynamics Stock Rockets On Upbeat Q3, Improved Full-Year Guidance - But Retail Sentiment Plummet...
A5 - 2025-04-02T12:42:00Z - AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ANGO_OUT_7 [2025-04-02 11:32:36 -0400] 1098 Bytes | 315 tokens | Cum: 1427 tkns (17.84% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance - AngioDynamics (NASDAQ:ANGO)**Date: 2025-04-02Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/general/health-care/25/04/44608672/medical-device-maker-angiodynamics-stock-jumps-on-better-than-expected-q3-earnings-upbeat-annual-guidanceAngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the consensus for a per-share loss of 13 cents.

The maker of medical Instruments and supplies reported sales of $72 million, up 9.2% year over year, beating the consensus of $70.3 million.

Read Next: FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals

Med Tech's net sales were $31.3 million, up 22.2%, driven by strength across all product lines, including Auryon sales o

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ANGO_OUT_9 [2025-04-02 11:32:45 -0400] 1098 Bytes | 299 tokens | Cum: 1841 tkns (23.01% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): f $13.9 million, up 17.3%, AngioVac sales of $6.8 million, up 23.1%, AlphaVac sales of $3 million, up 161.4%, and NanoKnife disposable sales of $4.9 million, which increased 16.2%.

Med Device net sales were $40.7 million, almost flat year over year.

Gross margin for the third quarter of fiscal 2025 was 54.0%, up 290 basis points versus a year ago.

Adjusted EBITDA was $1.3 million, compared to a $3.6 million loss in the third quarter of fiscal 2024.

"As we look ahead, we are well positioned to deliver profitable growth going forward...With our improved operating leverage and strong balance sheet, we can continue to prudently invest to support high impact initiatives while remaining on track to hit our fiscal year 2026 profitability targets," said Jim Clemmer, president and CEO.

Guidance: AngioDynamics expects its fiscal-year 2025 net sales of $285 million to $288 million, representin

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ANGO_OUT_11 [2025-04-02 11:32:47 -0400] 883 Bytes | 294 tokens | Cum: 2374 tkns (29.68% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-10-09T19:30:00Z - 3 Stocks Insiders Are Buying Heavily in October and Why
B2 - 2024-10-08T18:34:52Z - AngioDynamics Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
B3 - 2024-10-03T15:23:22Z - Why AngioDynamics Stock Is Crashing Today
B4 - 2024-07-16T20:05:27Z - AngioDynamics stock target raised on growth prospects - Investing.com
B5 - 2024-07-11T08:20:13Z - U.S. Autoimmune Disease Diagnostics (Systemic, Localized) Market Size, Share & Trends Analysis Report 2024-2030 - GlobeNewswire
B6 - 2024-05-22T16:18:00Z - AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ANGO_OUT_13 [2025-04-02 11:32:49 -0400] 578 Bytes | 162 tokens | Cum: 2538 tkns (31.72% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**3 Stocks Insiders Are Buying Heavily in October and Why**Date: Unknown DateSource: Unknown SourceURL: https://www.investing.com/analysis/3-stocks-insiders-are-buying-heavily-in-october-and-why-200652771Insiders have been making significant purchases in Eton Pharmaceuticals, AngioDynamics, and Tile Shop Holdings, indicating their confidence in these companies' prospects.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ANGO_OUT_15 [2025-04-02 11:32:50 -0400] 1123 Bytes | 312 tokens | Cum: 2900 tkns (36.25% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-02 8-K Item 7.01 Regulation FD Disclosure.

On April 2, 2025, AngioDynamics, Inc. (AngioDynamics) will host the virtual Cardiovascular Investor Event. The presentation slides are furnished herewith as Exhibit 99.1.

The presentation slides furnished pursuant to Item 7.01 of this Form 8-...

S2 - 2025-04-02 8-K Item 2.02 Results of Oper and Fin Cond.

On April 2, 2025, AngioDynamics, Inc. (AngioDynamics) issued a press release announcing financial results for the fiscal third quarter ended February 28, 2025. A copy of the press release is furnished herewith as Exhibit 9...

S4 - 2025-01-16 8-K Item 7.01 Regulation FD Disclosure.

On January 16, 2025, James Clemmer, President and Chf Exec Off, of AngioDynamics, Inc. (AngioDynamics), presented at the J.P. Morgan 43rd Annual Healthcare Conference. The presentation slides are furnished herewith as Exhibit 99.1.
...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ANGO_OUT_17 [2025-04-02 11:32:56 -0400] 1022 Bytes | 260 tokens | Cum: 3162 tkns (39.52% of 8k)
==========================================================================

Showing S2 (chunk 1 of 1): S2:
Item 2.02 Results of Operations and Financial Condition.

On April 2, 2025, AngioDynamics, Inc. (AngioDynamics) issued a press release announcing financial results for the fiscal third quarter ended February 28, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.

The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that Section. Furthermore, such information shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

ANGO_OUT_19 [2025-04-02 11:33:05 -0400] 4384 Bytes | 1264 tokens | Cum: 4568 tkns (57.10% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+-------------------------+------------------------+
| Volume: 1,392,040 | Perf Month: 17.32% | Option/Short: Yes / Yes | Sales Y/Y TTM: -13.06% |
+---------------------+----------------------+-------------------------+------------------------+
| Avg Volume: 691.75K | Perf Quarter: 21.99% | Short Float: 4.40% | ROE: -76.44% |
+---------------------+----------------------+-------------------------+------------------------+
| Rel Volume: 6.48 | Index: RUT | Short Ratio: 2.45 | ROI: -118.40% |
+---------------------+----------------------+-------------------------+------------------------+
| RSI (14): 64.67 | Market Cap: 446.74M | Short Interest: 1.70M | Sales Surprise: 2.43% |
+---------------------+----------------------+-------------------------+------------------------+
| ATR (14): 0.56 | Shs Outstand: 40.84M | Beta: 0.58 | EPS Surprise: 38.46% |
+---------------------+----------------------+-------------------------+------------------------+
| SMA20: 15.41% | Shs Float: 38.59M | Sales Q/Q: -7.88% | P/E: - |
+---------------------+----------------------+-------------------------+------------------------+
| SMA50: 7.04% | Inst Own: 81.98% | Sales past 5Y: 2.66% | Earnings: Apr 02 BMO |
+---------------------+----------------------+-------------------------+------------------------+
| SMA200: 34.43% | Insider Own: 4.63% | Employees: 748 | |
+---------------------+----------------------+-------------------------+------------------------+
| Perf Week: 11.63% | Insider Trans: 1.00% | Debt/Eq: 0.03 | |
+---------------------+----------------------+-------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: ANGIODYNAMICS INC (ANGO) by Nighan Warren JR (SVP Quality and Regulatory) on 2025-01-16
- Common Stock: 4060 shares at $12.31 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 286498000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -224721000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 11.045
Average Volume: 555293.39
30-Day High: 11.045
30-Day Low: 8.37

[Detailed Financials: Q2 2025]
- Total Assets: $291,550,000.0
- Total Liabilities: $104,782,000.0
- Total Equity: $186,768,000.0
- Current Assets: $175,360,000.0
- Current Liabilities: $88,595,000.0

[Income Statement: Q2 2025]
- Revenue: $72,845,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.26

[Cash Flow Statement: Q2 2025]
- Net Cash Flow: $-916,000

[Detailed Financials: Q1 2025]
- Total Assets: $293,628,000.0
- Total Liabilities: $97,046,000.0
- Total Equity: $196,582,000.0
- Current Assets: $172,594,000.0
- Current Liabilities: $76,699,000.0

[Income Statement: Q1 2025]
- Revenue: $67,491,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.31

[Cash Flow Statement: Q1 2025]
- Net Cash Flow: $-21,051,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ANGO_OUT_21 [2025-04-02 11:33:09 -0400] 676 Bytes | 167 tokens | Cum: 4961 tkns (62.01% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ANGO_IN_23 [2025-04-02 11:33:10 -0400] 126 Bytes | 29 tokens | Cum: 5078 tkns (63.48% of 8k)
==========================================================================

====================================
[2025-04-02 11:33:10] # Analysis Completed
Elapsed Time: 42.86 seconds